New drug cocktail shows promise against tough lung cancer before surgery

NCT ID NCT07492342

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new treatment approach for people with a specific type of lung cancer (KRAS G12C mutation) that can be removed by surgery. About 30 participants will receive a targeted pill (fulzerasib) for 6 weeks, followed by a short break, then 3 cycles of immunotherapy (sintilimab) plus chemotherapy before their surgery. The goal is to see if this combination can shrink or eliminate the tumor before the operation, potentially improving long-term outcomes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KRAS G12C MUTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Peking Union Medical College Hospital

    NOT_YET_RECRUITING

    Beijing, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The First Affiliated Hospital of Guangzhou Medical University

    RECRUITING

    Guangzhou, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The First Affiliated Hospital of Zhejiang University School of Medicine

    NOT_YET_RECRUITING

    Zhejiang, China

    Contact